Nicola Riccardo Pugliese1,2, Iacopo Fabiani1,2, Claudia Santini2, Ilaria Rovai2, Roberto Pedrinelli2, Andrea Natali3, Frank L Dini2. 1. Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Via Paradisa, 2, Pisa, Italy. 2. Cardiac, Thoracic and Vascular Department, University of Pisa, Via Paradisa, 2, Pisa, Italy. 3. Department of Clinical and Experimental Medicine, University of Pisa, Via Paradisa, 2, Pisa, Italy.
Abstract
AIMS: To characterize heart failure (HF) with mid-range ejection fraction (HFmrEF), combining cardiopulmonary exercise test, and exercise stress echocardiography. METHODS AND RESULTS: We studied 169 consecutive subjects (age 62.3 ± 11 years; 74% male): 30 healthy controls, 45 patients with HF and preserved EF (HFpEF), 40 HFmrEF, and 54 with HF and reduced EF (HFrEF). Left ventricular (LV) stroke volume (SV), EF, elastance, global longitudinal strain, E/E', oxygen consumption (VO2), and arterial-venous oxygen content difference (AVO2diff) were measured in all exercise stages. HFmrEF revealed baseline features intermediate between HFrEF and HFpEF, except for B-type natriuretic peptide levels, which was similar to HFpEF and significantly lower than HFrEF. Peak VO2 was not significantly different between HF groups. HFrEF exhibited a significantly lower peak SV as compared to either HFpEF or HFmrEF (74.3 ± 21.8 mL vs. 88.0 ± 17.4 mL and 96.5 ± 25.1 mL; P < 0.01), whereas peak heart rate was not significantly different between HF groups. A significantly reduced AVO2diff at peak exercise was apparent in HFpEF and HFmrEF (15.2 ± 3.3 mL/dL and 13.3 ± 4.2 mL/dL) vs. HFrEF (17.±6.6 mL/dL; P < 0.01), whereas no significant difference was reported between HFpEF and HFmrEF. Multivariate analysis in the overall population and all groups revealed peak parameters as independent predictors of peak VO2 (R2 = 0.90, P < 0.0001); AVO2diff showed the largest standardized regression coefficient. CONCLUSION: In HFpEF and HFmrEF, effort intolerance is predominantly due to peripheral factors (AVO2diff), whereas in HFrEF peak VO2 is restricted by low increases in SV. Individual therapy according to which component of VO2 is more impaired is advisable. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: To characterize heart failure (HF) with mid-range ejection fraction (HFmrEF), combining cardiopulmonary exercise test, and exercise stress echocardiography. METHODS AND RESULTS: We studied 169 consecutive subjects (age 62.3 ± 11 years; 74% male): 30 healthy controls, 45 patients with HF and preserved EF (HFpEF), 40 HFmrEF, and 54 with HF and reduced EF (HFrEF). Left ventricular (LV) stroke volume (SV), EF, elastance, global longitudinal strain, E/E', oxygen consumption (VO2), and arterial-venous oxygen content difference (AVO2diff) were measured in all exercise stages. HFmrEF revealed baseline features intermediate between HFrEF and HFpEF, except for B-type natriuretic peptide levels, which was similar to HFpEF and significantly lower than HFrEF. Peak VO2 was not significantly different between HF groups. HFrEF exhibited a significantly lower peak SV as compared to either HFpEF or HFmrEF (74.3 ± 21.8 mL vs. 88.0 ± 17.4 mL and 96.5 ± 25.1 mL; P < 0.01), whereas peak heart rate was not significantly different between HF groups. A significantly reduced AVO2diff at peak exercise was apparent in HFpEF and HFmrEF (15.2 ± 3.3 mL/dL and 13.3 ± 4.2 mL/dL) vs. HFrEF (17.±6.6 mL/dL; P < 0.01), whereas no significant difference was reported between HFpEF and HFmrEF. Multivariate analysis in the overall population and all groups revealed peak parameters as independent predictors of peak VO2 (R2 = 0.90, P < 0.0001); AVO2diff showed the largest standardized regression coefficient. CONCLUSION: In HFpEF and HFmrEF, effort intolerance is predominantly due to peripheral factors (AVO2diff), whereas in HFrEF peak VO2 is restricted by low increases in SV. Individual therapy according to which component of VO2 is more impaired is advisable. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Nasrien E Ibrahim; Yang Song; Christopher P Cannon; Gheorghe Doros; Patricia Russo; Angelo Ponirakis; Claire Alexanian; James L Januzzi Journal: ESC Heart Fail Date: 2019-07-03
Authors: Andreas B Gevaert; Stephan Mueller; Ephraim B Winzer; André Duvinage; Caroline M Van de Heyning; Elisabeth Pieske-Kraigher; Paul J Beckers; Frank Edelmann; Ulrik Wisløff; Burkert Pieske; Volker Adams; Martin Halle; Emeline M Van Craenenbroeck Journal: Front Physiol Date: 2022-02-10 Impact factor: 4.566
Authors: Caterina Maffeis; Andrea Rossi; Lorenzo Cannata; Camilla Zocco; Evgeny Belyavskiy; Aravind Kumar Radhakrishnan; Anna Feuerstein; Daniel Armando Morris; Elisabeth Pieske-Kraigher; Burkert Pieske; Frank Edelmann; Pier Luigi Temporelli Journal: ESC Heart Fail Date: 2022-01-05
Authors: Krzysztof Smarz; Tomasz Jaxa-Chamiec; Beata Zaborska; Maciej Tysarowski; Andrzej Budaj Journal: PLoS One Date: 2021-08-05 Impact factor: 3.240